Tomorrow the the Danish company Genmab will publish her past quarter's results. For this year the consensus of the revenue equals 1,08 billion Danish Krone. This is slightly lower than the 2015's revenue of 1,13 billion Danish Krone.
The analysts foresee for 2016 a net profit of 283 million Danish Krone. For the current year the consensus of the result per share is a of profit 4,71 Danish Krone. Based on this the price/earnings-ratio equals a quite high 259,66.
Dividend payments are not expected of Genmab . The average dividend of the pharmaceutical sector equals 1,32 percent.
Based on the number of outstanding shares Genmab 's market capitalisation equals 72,81 billion Danish Krone.The stock traded at 12.43 1,31 percent lower at 1223 Danish Krone.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.